IMIC(SZ:000516) Sou Hu Cai Jing·2025-12-16 14:57Core Viewpoint - International Medicine (000516) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of December 16, 2025, the stock closed at 4.5 yuan, down 1.1%, with a turnover rate of 0.52% [1]. - The trading volume was 113,800 hands, with a transaction amount of 51.2548 million yuan [1]. - On December 16, the net outflow of main funds was 4.082 million yuan, accounting for 7.96% of the total transaction amount [1]. - The net outflow of speculative funds was 1.8504 million yuan, representing 3.61% of the total transaction amount [1]. - Retail investors had a net inflow of 5.9323 million yuan, making up 11.57% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions in the past 90 days is 5.5 yuan [3].